Literature DB >> 3561781

Risk factors for Guillain-Barré syndrome.

R A Kaslow, J Z Sullivan-Bolyai, R C Holman, B Hafkin, R C Dicker, L B Schonberger.   

Abstract

In 100 cases of Guillain-Barré syndrome (GBS) reported from 10 metropolitan areas to the Centers for Disease Control (CDC) after the 1976-77 influenza vaccination campaign and matched associate or spouse controls, we searched for risk factors for GBS other than A/New Jersey/1976 influenza vaccination and acute respiratory infection. The 47 vaccinated cases recalled influenza vaccination in past years less frequently than did controls (p less than 0.025). Cases and controls did not differ in the number of previous vaccinations or in interval from last vaccination. Cases also gave a history of allergy less frequently than controls. There were no other significant differences.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3561781     DOI: 10.1212/wnl.37.4.685

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Herpes simplex virus specific antibody determined by immunoblotting in cerebrospinal fluid of a patient with the Guillain-Barré syndrome.

Authors:  H J Bernsen; A M Van Loon; R F Poels; W I Verhagen; C W Frenken
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

2.  Polyradiculoneuritis following botulinum toxin therapy.

Authors:  B A Haug; D Dressler; H W Prange
Journal:  J Neurol       Date:  1990-02       Impact factor: 4.849

3.  Guillain-barré syndrome following influenza vaccination: causal or coincidental?

Authors:  James J Sejvar; Dina Pfeifer; Lawrence B Schonberger
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

4.  A prospective study of acute idiopathic neuropathy. II. Antecedent events.

Authors:  J B Winer; R A Hughes; M J Anderson; D M Jones; H Kangro; R P Watkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.